Posted by Michael Wonder on 09 Apr 2018
Public hearing on 13 June 2018
9 April 2018 - Citizens to be consulted on quinolone and fluoroquinolone antibiotics.
The EMA has opened registration for its next public hearing which will take place on 13 June 2018 at EMA’s premises. The public hearing will give a voice to patients, doctors, nurses, pharmacists, researchers and everyone else who wants to share experience with quinolones and fluoroquinolones, a class of antibiotics widely prescribed in the European Union.
The public hearing is part of a review being carried out by EMA’s safety committee, the Pharmacovigilance Risk Assessment Committee, that is investigating reports of serious persistent side effects mainly affecting muscles, joints and the nervous system. Some of these side effects have been reported in patients with infections that were not severe and could have been treated with other antibiotics.
